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PCN18 ECONOMIC IMPACT OF SEVERE INFUSION REACTIONS IN PATIENTS WITH COLORECTAL CANCER TREATED WITH CETUXIMAB
Foley KA y 1 , Wang PF 2 , Barber B 2 , Long SR 3 , Bagalman JE 4 , Zhao Z 2 1 Thomas Jefferson University, Philadelphia, PA, USA, 2 Amgen, Inc., Thousand Oaks, CA, USA, 3 Thomson Reuters, Hampden, ME, USA, 4 Thomson Reuters, WASHINGTON, DC, USA OBJECTIVES: To assess the incidence rate and risk factors of severe infusion reactions (IRs), and to quantify the costs associated with their management in patients with colorectal cancer (CRC) treated with cetuximab. METHODS: Using administrative claims of a US national commercially insured population, the study evaluates patients with CRC receiving cetuximab treatment from 2004 to 2006. An algorithm was developed to identify IRs using a combination of three indicators: outpatient diagnoses of signs/symptoms of IRs, outpatient treatment for IRs, and ER visits or hospitalizations for IRs. IRs were categorized as severe based on the occurrence of an ER visit/ hospitalization with an IR admitting diagnosis; or presence of both outpatient diagnosis of IR signs/symptoms and outpatient IR treatment. Total costs associated with each cetuximab administration were calculated. A logistic regression was run to identify risk factors for IRs. A Generalized Linear Model regression controlling for demographic and clinical characteristics was conducted to quantify additional economic impact of severe IRs. RESULTS: A total of 1,122 patients were identifi ed with 12,367 cetuximab administrations. The incidence of severe IRs was 8.4%. Approximately 38% of patients experiencing severe IRs required an ER visit or hospitalization. Mean adjusted costs were $6,339 for administrations resulting in a severe IR that required outpatient treatment only; $13,174 for administrations resulting in a severe IR that required an ER visit or hospitalization; and $4,450 for administrations without an IR. Younger age was associated with a statistically higher likelihood of IRs. Living in states with high pollen counts also had a trend of increased likelihood of severe IRs, although it was not statistically signifi cant. CONCLUSIONS: The rate of severe IRs with cetuximab in clinical practice was found to be higher than that reported in the product labeling and clinical trials. Total costs associated with managing severe IRs to payers were substantial. Myeloid growth factors are used to treat and prevent chemotherapyinduced neutropenia (CIN). Filgrastim and its long-acting version pegfi lgrastim are granulocyte colony-stimulating factors (G-CSF), whereas sargramostim is a dual granulocyte-macrophage colony-stimulating factor (GM-CSF). This study analyzed the budget impact of substituting GM-CSF for G-CSF in the management of CIN from the perspective of a US health plan. METHODS: A spreadsheet model was developed to compute annual and per-member-per-month (PMPM) costs associated with CSFs. Inputs included cancer prevalence, the proportion of patients receiving chemotherapy and G/GM-CSFs, incidence and treatment cost of relevant adverse events (e.g., bone pain), and G/GM-CSF drug acquisition and administration costs. Incidence and cost of infection-and febrile neutropenia-related hospitalizations, based on recent analysis of medical insurance claims data, were also used. Cost savings (2006 USD) were assessed for utilization share switches from G-CSF to GM-CSF. RESULTS: For a health plan with 1 million members, an estimated 976 patients received G/GM-CSF annually. Modifying baseline utilization shares for pegfi lgrastim, fi lgrastim, and sargramostim of 70/30/0%, respectively, to alternative shares of 50/25/25% yielded almost $2 million in annual cost savings, or $0.161 PMPM. Most of the cost savings were attributed to CSF acquisition and administration costs (81.8%), with lesser savings also observed for hospitalizations (14.6%) and adverse events (3.6%). Savings for patients switching from pegfi lgrastim were greater than for patients switching from fi lgrastim. Results were sensitive to assumptions for drug cost and frequency of administration, but cost savings were observed for most scenarios. CONCLUSIONS: This study suggests that health plans can realize substantial cost savings by substituting sargramostim for fi lgrastim and pegfi lgrastim in CIN patients. With 25% of sargramostim substitution, cost savings could reach more than 16 cents PMPM for a typical US health plan. 3 The West Clinic, Memphis, TN, USA OBJECTIVES: Pemetrexed plus cisplatin (Cis/Pem) was recently approved in the US as initial treatment for advanced nonsquamous NSCLC. We developed a budget impact model to estimate the effect on a US health plan budget of adopting Cis/Pem for this new indication. METHODS: A deterministic Excel-based budget impact model was developed from the perspective of a one million member US health plan over a one-year time horizon. A survey of nine US thoracic oncologists was used to quantify the impact of introducing Cis/Pem as fi rst-line therapy on the frequency of chemotherapy use and the choice of fi rst-and second-line regimens. Results were calculated from SEER incidence rates and the anticipated changes in fi rst-and second-line regimen utilization rates. The costs associated with each regimen were based on Medicare reimbursement rates and a claims database analysis. Model outputs included health plan total cost, cost per patient per year, and per member per month (PMPM) costs. RESULTS: Following the adoption of Cis/Pem, total cost per patient per year for advanced NSCLC is estimated to decrease by $702 from $67,539 to $66,837. Anticipating that the number of NSCLC patients receiving treatment over the course of one year would increase slightly, a net additional cost to the health plan of $35,512 is estimated. Overall a neutral PMPM cost ($0.00) is expected. Most sensitivity analyses produce PMPM costs between $0.02 and $0.02. CONCLUSIONS: Introduction of Cis/Pem as fi rst-line therapy is anticipated to reduce the use of less expensive doublet regimens including gemcitabine and paclitaxel; however, it is also anticipated to reduce the use of more expensive triplet regimens containing bevacizumab. When Cis/Pem is used as fi rst-line therapy, alternative, and often less expensive, regimens are recommended for use as second-line therapy. Overall, the adoption of Cis/Pem as fi rst-line therapy for advanced nonsquamous NSCLC is anticipated to be budget neutral.
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PCN20 THE BUDGETARY IMPACT OF PEMETREXED PLUS CISPLATIN AS FIRST-LINE THERAPY FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
PCN21 BUDGET IMPACT ANALYSIS OF NON -SMALL CELL LUNG CARCINOMA (NSCLC) TREATMENT WITH ERLOTINIB IN POLISH SETTING
Orlewska E 1 , Szczesna A 2 , Szkultecka-Debek M 3 1 Centrum Farmakoekonomiki, Warsaw, Poland, 2 Regional Lung Diseases Hospital, Otwock, Poland, 3 Roche Polska, Warsaw, Poland OBJECTIVES: to assess the fi nancial consequences of the introduction of erlotinib as second/third line treatment of patients with IIIB/IV NSCLC in Poland. METHODS: Two scenarios were compared: "baseline scenario" where 96% patients received docetaxel 75 mg/m2 every 21 days and 4% received pemetrexed 500 mg/m2 every 21 days versus "new scenario" where 100% patients were treated with erlotinib 150 mg/ d. To assess the impact of disease progression, survival, safety profi le and estimate costs after starting a therapy, a Markov health-state model was developed. Budget impact was derived by simulating a patient cohort progress through the model and allowing for new eligible patients to enter the model each year. For each scenario the model computes annual costs for 3-years time horizon. Only direct medical costs were included and estimated from the health care payer perspective. All costs were assessed in PLN (1 EUR 4.03 PLN, 2008) , without discounting. Extreme scenario sensitivity analyses were performed. RESULTS: Assuming that the number of patients eligible for erlotinib therapy would be 200 annually, substitution of "baseline scenario" with erlotinib is expected to reduce expenditure by 251,344 PLN, 517,116 PLN and 533,012 PLN in the 1st, 2nd and 3rd year, respectively (1,301,472 PLN over 3 years). Savings are mostly associated with oral administration of erlotinib. Sensitivity analysis shows that depending on assumptions regarding the costs of intravenous administration of docetaxel and pemetrexed or market share of docetaxel and pemetrexed, substitution with erlotinib could result in savings of up to 1,358,635 PLN over 3 years or to cost increases of up to 508,732 PLN over 3 years. CONCLUSIONS: Given the results of this budget impact simulation in the treatment of patients with second/third line metastatic NSCLC, erlotinib offers potential cost-savings to docetaxel and pemetrexed. We also reviewed charge and reimbursement data for clorfarabine for the same time period. All costs were adjusted to 2008 dollars. RESULTS: During the study period for the post-approval analysis, we treated 23 patients with clorfarabine; of these, only 5 (22%) were for ALL, 13 (56%) for acute myelogenous leukemia and 5 (22%) for other indications. For the ALL population, we had a positive reimbursement margin, and reimbursement to charge ratio was 77%. For all indications, the overall reimbursement to charge ratio for clorfarabine was 53%. Actual budget impact was $1,105,598; less than the $2,430,000 predicted from the pre-approval model.
PCN22 PHARMACOECONOMIC APPLICATIONS IN FORMULARY MANAGEMENT: BUDGET IMPACT ANALYSIS OF CLORFARABINE AT A MAJOR CANCER CENTER
CONCLUSIONS:
The result of the post-approval budget impact analysis of clorfarabine was lower than that estimated by the pre-approval model. Our pre-approval model included only ALL patients and overestimated the number of patients actually treated. Major factors driving the difference between the pre-and post-approval studies were actual drug cost per dose, actual number of doses per patient, and off-label usage. Future studies will include estimation of off-label usage in the preapproval model.
